The growing global cell therapy market is projected to reach more than $9 billion by2028. With such explosive growth and increasing demand for regenerative medicines, PPD, the clinical research business of Thermo Fisher Scientific, conducted asurvey in 2021 of executives engaged in cell therapy clinical trials at pharmaceutical and biopharmaceutical companies. 

The survey’s aim was to gain insights into the biggest challenges facing sponsor organizations and the solutions to those challenges offered by contract research organizations (CROs)that respondents find most satisfactory. Typical challenges investigated in the survey relateto chemistry, manufacturing and controls (CMC); logistics and storage; CRO project teamsand subject matter experts (SMEs); and patient follow up. The survey findings also revealedinsights about ongoing and planned cell therapy trials. Keep reading to learn more about thesurvey results.